Effects of Silibinin and Its Intravenous Formulation on Hepatitis C Virus
Author Information
Author(s): Jessica Wagoner, Chihiro Morishima, Tyler N. Graf, Nicholas H. Oberlies, Elodie Teissier, Eve-Isabelle Pécheur, John E. Tavis, Stephen J. Polyak
Primary Institution: University of Washington
Hypothesis
Silibinin and its intravenous formulation SIL exhibit differential effects on the hepatitis C virus lifecycle and inflammation.
Conclusion
SIL shows stronger antiviral activity against HCV compared to silibinin, particularly in inhibiting viral replication and inflammation.
Supporting Evidence
- SIL inhibited HCV RNA levels in vivo when administered intravenously.
- Silibinin did not significantly inhibit HCV replication in certain cell lines.
- Both formulations inhibited T cell proliferation to similar degrees.
Takeaway
This study shows that two forms of a plant extract can help fight a virus that causes liver disease, but they work in different ways.
Methodology
The study involved in vitro assays to compare the antiviral and anti-inflammatory effects of silibinin and its intravenous formulation SIL on HCV.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo efficacy.
Participant Demographics
Healthy subjects provided blood samples for the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website